Tech Company Inital Public Offerings
Galera Therapeutics IPO
Galera Therapeutics, based in Malvern, debuted as a public company on 11/6/2019.
Transaction Overview
Company Name
Announced On
11/6/2019
Transaction Type
IPO
Amount
$60,000,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds together with its existing cash as follows: approximately $67.5 million to advance the clinical development of GC4419 for the reduction of SOM in patients with HNC receiving radiotherapy, including to complete our ongoing ROMAN trial, seek regulatory approval and fund pre-commercialization activities of GC4419; approximately $6.0 million to advance the clinical development of GC4419 for the reduction of the incidence of radiotherapy-induced esophagitis, including to fund our planned Phase 2a trial; approximately $12.5 million to advance the clinical development of GC4711 to increase the anti-cancer efficacy of SBRT, including to complete our ongoing pilot Phase 1b/2a trial in patients with LAPC and to fund our planned Phase 1b/2a trial in patients with NSCLC; and the remainder to fund new and ongoing research and development activities, including to develop additional dismutase mimetics and an oral formulati
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2 West Liberty Blvd. 110
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Not Recorded
Overview
Galera Therapeutics (Nasdaq: GRTX) develops therapeutic agents for preventing damage to normal tissues during the radiation treatment of cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mel Sorensen
Chief Financial Officer
Joel Sussman
Chief Medical Officer
Jon Holmlund
Chief Operating Officer
Robert Beardsley
Chief Scientific Officer
Dennis Riley
VP - Bus. Development
Arthur Fratamico
VP - Bus. Development
Stephen Ross
Browse more venture capital transactions:
Prev: 11/6/2019: Imbed Biosciences venture capital transaction
Next: 11/6/2019: Shape Therapeutics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs